<?xml version='1.0' encoding='utf-8'?>
<document id="28867721"><sentence text="Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats."><entity charOffset="21-32" id="DDI-PubMed.28867721.s1.e0" text="Oxethazaine" /><entity charOffset="36-45" id="DDI-PubMed.28867721.s1.e1" text="Midazolam" /><pair ddi="false" e1="DDI-PubMed.28867721.s1.e0" e2="DDI-PubMed.28867721.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s1.e0" e2="DDI-PubMed.28867721.s1.e1" /></sentence><sentence text="There have been few reports concerning to the drug-drug interactions (DDIs) with OTC drugs although an increase in the use of OTC drugs in recent years" /><sentence text=" This current study was conducted to clarify the DDIs through CYP3A inhibition by oxethazaine (OXZ), an antacid available as an OTC drug"><entity charOffset="82-93" id="DDI-PubMed.28867721.s3.e0" text="oxethazaine" /><entity charOffset="95-98" id="DDI-PubMed.28867721.s3.e1" text="OXZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s3.e0" e2="DDI-PubMed.28867721.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s3.e0" e2="DDI-PubMed.28867721.s3.e1" /></sentence><sentence text=" Midazolam (MDZ) was used as a probe drug for CYP3A activity"><entity charOffset="1-10" id="DDI-PubMed.28867721.s4.e0" text="Midazolam" /><entity charOffset="12-15" id="DDI-PubMed.28867721.s4.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s4.e0" e2="DDI-PubMed.28867721.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s4.e0" e2="DDI-PubMed.28867721.s4.e1" /></sentence><sentence text=" In an in vivo study, a single oral dose of OXZ (50 mg/kg) was administered to rats 30, 60, or 120 min before oral MDZ administration (15 mg/kg)"><entity charOffset="44-47" id="DDI-PubMed.28867721.s5.e0" text="OXZ" /><entity charOffset="115-117" id="DDI-PubMed.28867721.s5.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s5.e0" e2="DDI-PubMed.28867721.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s5.e0" e2="DDI-PubMed.28867721.s5.e1" /></sentence><sentence text=" Serum concentrations of MDZ were analyzed by HPLC, and its pharmacokinetic parameters were compared with a water-treated control group"><entity charOffset="25-27" id="DDI-PubMed.28867721.s6.e0" text="MDZ" /></sentence><sentence text=" The inhibitory effect of OXZ on MDZ 1'-hydroxylation (MDZ 1'-OH) activity was investigated in vitro using rat liver and intestinal microsomes"><entity charOffset="26-28" id="DDI-PubMed.28867721.s7.e0" text="OXZ" /><entity charOffset="33-35" id="DDI-PubMed.28867721.s7.e1" text="MDZ" /><entity charOffset="55-57" id="DDI-PubMed.28867721.s7.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s7.e0" e2="DDI-PubMed.28867721.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s7.e0" e2="DDI-PubMed.28867721.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28867721.s7.e0" e2="DDI-PubMed.28867721.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28867721.s7.e1" e2="DDI-PubMed.28867721.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28867721.s7.e1" e2="DDI-PubMed.28867721.s7.e2" /></sentence><sentence text=" Pretreatment of OXZ 120 min before MDZ administration significantly increased the area under the serum concentration-time curve (AUC0-∞) of MDZ six-fold compared to the control group without a change in elimination half-life (t1/2)"><entity charOffset="17-19" id="DDI-PubMed.28867721.s8.e0" text="OXZ" /><entity charOffset="36-38" id="DDI-PubMed.28867721.s8.e1" text="MDZ" /><entity charOffset="141-143" id="DDI-PubMed.28867721.s8.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s8.e0" e2="DDI-PubMed.28867721.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s8.e0" e2="DDI-PubMed.28867721.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28867721.s8.e0" e2="DDI-PubMed.28867721.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28867721.s8.e1" e2="DDI-PubMed.28867721.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28867721.s8.e1" e2="DDI-PubMed.28867721.s8.e2" /></sentence><sentence text=" In contrast, OXZ pretreatment 30 or 60 min before MDZ administration did not show any remarkable change in MDZ pharmacokinetic parameters"><entity charOffset="14-16" id="DDI-PubMed.28867721.s9.e0" text="OXZ" /><entity charOffset="51-53" id="DDI-PubMed.28867721.s9.e1" text="MDZ" /><entity charOffset="108-110" id="DDI-PubMed.28867721.s9.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s9.e0" e2="DDI-PubMed.28867721.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s9.e0" e2="DDI-PubMed.28867721.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28867721.s9.e0" e2="DDI-PubMed.28867721.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28867721.s9.e1" e2="DDI-PubMed.28867721.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28867721.s9.e1" e2="DDI-PubMed.28867721.s9.e2" /></sentence><sentence text=" The in vitro study showed that OXZ inhibited MDZ 1'-OH activity in a concentration-dependent manner both in liver and intestinal microsomes"><entity charOffset="32-34" id="DDI-PubMed.28867721.s10.e0" text="OXZ" /><entity charOffset="46-48" id="DDI-PubMed.28867721.s10.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s10.e0" e2="DDI-PubMed.28867721.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s10.e0" e2="DDI-PubMed.28867721.s10.e1" /></sentence><sentence text=" These results suggested that OXZ increases serum MDZ concentration presumably by the inhibition of liver and/or intestinal CYP3A activity"><entity charOffset="30-32" id="DDI-PubMed.28867721.s11.e0" text="OXZ" /><entity charOffset="50-52" id="DDI-PubMed.28867721.s11.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.28867721.s11.e0" e2="DDI-PubMed.28867721.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28867721.s11.e0" e2="DDI-PubMed.28867721.s11.e1" /></sentence><sentence text=" OXZ was predicted to cause the DDIs mediated by CYP3A inhibition, although this effect depended on the dose interval"><entity charOffset="1-3" id="DDI-PubMed.28867721.s12.e0" text="OXZ" /></sentence><sentence text="" /></document>